Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy
Public ClinicalTrials.gov record NCT00278993. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Multicenter, Open Label, Two Stage Design Study Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multi-centre, phase II, open-label, two-stage design, single-arm study in patients with hormone-refractory prostate cancer (HRPC) with advanced (rising PSA) and/or metastatic disease and who have had prior anti-androgen therapy. The study will further explore the efficacy of E7389 by enrollment of patients into two strata: those who have had no prior systemic chemotherapy for their disease (except for mitoxantrone and estramustine), and those who failed no more than one previous chemotherapeutic regimen with tubulin-binding agents such as docetaxel.
Study identification
- NCT ID
- NCT00278993
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 108 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2006 (Type not available)
- Primary completion
- Jan 2008 (Actual)
- Completion
- Jan 2008 (Actual)
- Last update posted
- Jul 14, 2014
2006 – 2008
United States locations
- U.S. sites
- 18
- U.S. states
- 9
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Dr. Robert Jotte | Denver | Colorado | 80218 | — |
| Melbourne Internal Medicine Associates | Melbourne | Florida | 32901 | — |
| Ocala Oncology Center PL | Ocala | Florida | 34474 | — |
| Central Indiana Cancer Centers | Indianapolis | Indiana | 46227 | — |
| Minnesota Hematology Oncology | Burnsville | Minnesota | 33557 | — |
| Missouri Cancer Associates | Columbia | Missouri | 65201 | — |
| New York Oncology Hematology, P.C. | Albany | New York | 12208 | — |
| St. Luke's Roosevelt Hospital Center | New York | New York | 10019 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Raleigh Hematology Oncology Associates PL | Raleigh | North Carolina | 27607 | — |
| US Oncology | Dallas | Texas | 75204 | — |
| Mary Crowley Medical Research Center | Dallas | Texas | 75246 | — |
| El Paso Cancer Treatment Center | El Paso | Texas | 79915 | — |
| Texas Oncology PA | Fort Worth | Texas | 76104 | — |
| Texas Oncology PA | Tyler | Texas | 75702 | — |
| Tyler Cancer Center | Tyler | Texas | 75702 | — |
| Deke Slayton Cancer Center | Webster | Texas | 77598 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23505 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00278993, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 14, 2014 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00278993 live on ClinicalTrials.gov.